Niranjan Awasthi

2.3k total citations
65 papers, 1.9k citations indexed

About

Niranjan Awasthi is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Niranjan Awasthi has authored 65 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 26 papers in Molecular Biology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Niranjan Awasthi's work include Pancreatic and Hepatic Oncology Research (32 papers), Gastric Cancer Management and Outcomes (13 papers) and Cancer Mechanisms and Therapy (8 papers). Niranjan Awasthi is often cited by papers focused on Pancreatic and Hepatic Oncology Research (32 papers), Gastric Cancer Management and Outcomes (13 papers) and Cancer Mechanisms and Therapy (8 papers). Niranjan Awasthi collaborates with scholars based in United States, China and Switzerland. Niranjan Awasthi's co-authors include Roderich E. Schwarz, Margaret A. Schwarz, B.J. Wagner, Stefan Hinz, Changhua Zhang, Rolf A. Brekken, Urs von Holzen, Anna Schwarz, Zhen Xiang and Noelle S. Williams and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Niranjan Awasthi

63 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Niranjan Awasthi United States 25 889 703 356 338 294 65 1.9k
Jiyun Yoo South Korea 23 1.2k 1.4× 413 0.6× 174 0.5× 245 0.7× 143 0.5× 53 1.8k
E. Ioachim Greece 24 674 0.8× 492 0.7× 142 0.4× 317 0.9× 171 0.6× 79 1.7k
Yoshinobu Toda Japan 26 1.2k 1.3× 496 0.7× 112 0.3× 440 1.3× 287 1.0× 50 2.0k
Jennifer A. Doll United States 21 921 1.0× 363 0.5× 115 0.3× 371 1.1× 261 0.9× 29 1.6k
R. Kath Germany 18 433 0.5× 454 0.6× 203 0.6× 109 0.3× 176 0.6× 55 1.3k
Douglas Armellino United States 15 1.3k 1.5× 738 1.0× 76 0.2× 401 1.2× 123 0.4× 18 2.3k
Shi‐Ming Tu United States 19 857 1.0× 781 1.1× 54 0.2× 397 1.2× 1.1k 3.7× 72 2.1k
Arianna Giacomini Italy 25 1.2k 1.4× 407 0.6× 51 0.1× 356 1.1× 224 0.8× 67 2.0k

Countries citing papers authored by Niranjan Awasthi

Since Specialization
Citations

This map shows the geographic impact of Niranjan Awasthi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niranjan Awasthi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niranjan Awasthi more than expected).

Fields of papers citing papers by Niranjan Awasthi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niranjan Awasthi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niranjan Awasthi. The network helps show where Niranjan Awasthi may publish in the future.

Co-authorship network of co-authors of Niranjan Awasthi

This figure shows the co-authorship network connecting the top 25 collaborators of Niranjan Awasthi. A scholar is included among the top collaborators of Niranjan Awasthi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niranjan Awasthi. Niranjan Awasthi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Awasthi, Niranjan, et al.. (2023). Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models. Frontiers in Oncology. 13. 1145999–1145999. 2 indexed citations
2.
Awasthi, Niranjan, et al.. (2022). Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy. Molecular Cancer Therapeutics. 21(7). 1149–1159. 4 indexed citations
3.
Zhou, Zhijun, Guanggai Xia, Zhen Xiang, et al.. (2019). A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis. Clinical Cancer Research. 25(11). 3317–3328. 94 indexed citations
4.
Awasthi, Niranjan, Margaret A. Schwarz, Changhua Zhang, & Roderich E. Schwarz. (2018). Augmentation of Nab -Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models. Molecular Cancer Therapeutics. 17(11). 2353–2364. 10 indexed citations
5.
Awasthi, Niranjan, et al.. (2018). Pancreatic ductal adenocarcinoma cell secreted extracellular vesicles containing ceramide-1-phosphate promote pancreatic cancer stem cell motility. Biochemical Pharmacology. 156. 458–466. 23 indexed citations
6.
Lal, Charitharth Vivek, et al.. (2016). Endothelial Monocyte-Activating Polypeptide II Mediates Macrophage Migration in the Development of Hyperoxia-Induced Lung Disease of Prematurity. American Journal of Respiratory Cell and Molecular Biology. 55(4). 602–612. 20 indexed citations
7.
Awasthi, Niranjan & Roderich E. Schwarz. (2015). Profile of nintedanib in the treatment of solid tumors: the evidence to date. OncoTargets and Therapy. 8. 3691–3691. 57 indexed citations
8.
Wu, Ying, Wei Chen, Zhen Xiang, et al.. (2015). CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. Cancer Letters. 359(2). 335–343. 79 indexed citations
9.
Awasthi, Niranjan, Changhua Zhang, Anna Schwarz, et al.. (2014). Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer. Molecular Cancer Therapeutics. 13(5). 1032–1043. 18 indexed citations
10.
Ostapoff, Katherine T., Niranjan Awasthi, Bercin Kutluk Cenik, et al.. (2013). PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer. Molecular Cancer Therapeutics. 12(7). 1190–1201. 62 indexed citations
11.
Awasthi, Niranjan, et al.. (2013). The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer. International Journal of Oncology. 43(5). 1627–1635. 30 indexed citations
12.
Awasthi, Niranjan, Chenyue Zhang, Anna Schwarz, et al.. (2013). Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. Carcinogenesis. 34(10). 2361–2369. 108 indexed citations
13.
Awasthi, Niranjan, Changhua Zhang, Stefan Hinz, Margaret A. Schwarz, & Roderich E. Schwarz. (2013). Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. Journal of Experimental & Clinical Cancer Research. 32(1). 12–12. 29 indexed citations
14.
Awasthi, Niranjan, et al.. (2012). BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer. Molecular Cancer Therapeutics. 11(12). 2644–2653. 66 indexed citations
15.
Zhang, Changhua, Niranjan Awasthi, Margaret A. Schwarz, & Roderich E. Schwarz. (2012). Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer. Journal of Surgical Research. 182(2). 227–234. 17 indexed citations
16.
Awasthi, Niranjan, Margaret A. Schwarz, & Roderich E. Schwarz. (2011). Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. HPB. 13(9). 597–604. 20 indexed citations
17.
Awasthi, Niranjan, et al.. (2011). The efficacy of a novel, dual PI3K/mTOR inhibitor NVP‐BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. Journal of Cellular Biochemistry. 113(3). 784–791. 77 indexed citations
18.
Awasthi, Niranjan, Margaret A. Schwarz, & Roderich E. Schwarz. (2010). Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer. Cancer Biology & Therapy. 10(1). 99–107. 18 indexed citations
19.
Schwarz, Roderich E., et al.. (2009). EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic Cancer. Annals of Surgical Oncology. 17(5). 1442–1452. 23 indexed citations
20.
Schwarz, Roderich E., et al.. (2009). An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer. Surgery. 146(2). 241–249. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiyun Yoo Breakdown of academic impact, for papers by E. Ioachim Breakdown of academic impact, for papers by Yoshinobu Toda Breakdown of academic impact, for papers by Jennifer A. Doll Breakdown of academic impact, for papers by R. Kath Breakdown of academic impact, for papers by Douglas Armellino Breakdown of academic impact, for papers by Shi‐Ming Tu Breakdown of academic impact, for papers by Arianna Giacomini
Rankless by CCL
2026